Source:http://linkedlifedata.com/resource/pubmed/id/18950459
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2008-11-27
|
| pubmed:abstractText |
Many controlled clinical trials have proven that rituximab improves the clinical outcome of patients with mature B cell lymphoma. This study was conducted to assess the contribution of rituximab in the actual clinical practice. Patients with newly diagnosed mature B cell lymphoma treated at 20 National Hospital Organization hospitals from January 2000 to December 2004 were consecutively registered. Rituximab was approved in September 2002 for indolent B cell lymphoma and in September 2003 for aggressive B cell lymphoma in Japan. The patients were divided into two groups depending on whether they received induction therapy containing rituximab. The endpoint was to evaluate the rituximab benefit based on 2-year progression-free survival (PFS) and 2-year overall survival (OS). A total 1126 patients received chemotherapies. Of these, 762 were diagnosed as diffuse large B cell lymphoma (DLBCL) and 215 as follicular lymphoma (FL). PFS and OS were markedly improved in the rituximab group compared with the non-rituximab group in patients with DLBCL (both P < 0.001) and in patients with FL (P < 0.001 and P = 0.003 respectively). Rituximab, when used for remission induction therapy, significantly improved the clinical outcome of the mature B cell lymphoma patient in actual clinical practice.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1365-2141
|
| pubmed:author |
pubmed-author:HanadaShuichiS,
pubmed-author:HoribeKeizoK,
pubmed-author:HottaTomomitsuT,
pubmed-author:InoueNobumasaN,
pubmed-author:KawanoFumioF,
pubmed-author:NagaiHirokazuH,
pubmed-author:NishiuraTetsuoT,
pubmed-author:OkamuraSeiichiS,
pubmed-author:SawamuraMorioM,
pubmed-author:SunamiKazutakaK,
pubmed-author:UikeNaokuniN,
pubmed-author:WatanabeTomoyukiT,
pubmed-author:YanoTakahiroT
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
143
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
672-80
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:18950459-Adolescent,
pubmed-meshheading:18950459-Adult,
pubmed-meshheading:18950459-Aged,
pubmed-meshheading:18950459-Aged, 80 and over,
pubmed-meshheading:18950459-Antibodies, Monoclonal,
pubmed-meshheading:18950459-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18950459-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18950459-Disease-Free Survival,
pubmed-meshheading:18950459-Female,
pubmed-meshheading:18950459-Humans,
pubmed-meshheading:18950459-Kaplan-Meier Estimate,
pubmed-meshheading:18950459-Lymphoma, B-Cell,
pubmed-meshheading:18950459-Lymphoma, Follicular,
pubmed-meshheading:18950459-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:18950459-Male,
pubmed-meshheading:18950459-Middle Aged,
pubmed-meshheading:18950459-Proportional Hazards Models,
pubmed-meshheading:18950459-Remission Induction,
pubmed-meshheading:18950459-Retrospective Studies,
pubmed-meshheading:18950459-Survival Rate,
pubmed-meshheading:18950459-Treatment Outcome,
pubmed-meshheading:18950459-Young Adult
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
|
| pubmed:affiliation |
Clinical Research Centre, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan. nagaih@nnh.hosp.go.jp
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|